Skip to Content

Committed to Safety: As we resume services, we are taking all necessary precautions to keep you safe while we care for you. Limited visitation is now in place. Review all our visitor policies and precautions. Get more information on COVID-19.

Clinical Trials Search Results

Showing 1-4 of 4

Sorted By:

  • Lung Map

    A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study)

  • Merck MK7902-007

    A Phase 3, randomized, double-blind trial of pembrolizumab (MK-3475) with or without lenvatinib (E7080/MK-7902) in participants with treatment-naïve, metastatic non-small cell lung cancer (NSCLC) whose tumors have a tumor proportion score (TPS) greater than or equal to 1%.

  • SWOG S1400F

    A Phase II Study of MEDI4736 (Durvalumab) plus Tremelimumab as Therapy for Patients with Previously Treated ANTI-PD-1/PD-L1 Resistant Stage IV Squamous Cell Lung Cancer (Lung-MAP Non-Match Sub-Study).

  • SWOG S1900A

    A Phase II Study of Rucaparib in Patients with Genomic LOH High And/Or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study).